Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2014

View Archived Issues

Third milestone achieved in GenVec and Novartis collaboration

UCB and MRC Technology sign exclusive license agreement

Preclinical characterization of a novel N-glucoside SGLT2 inhibitor

Shire reviews activities of fourth quarter 2013

Investigators identify a potential prognostic marker for CRPC

Sato Pharmaceutical discloses new SLC22A12 inhibitors

Novel GPR119 receptor agonists patented

Results presented from phase I study of ridaforolimus and vorinostat in RCC

Endo Pharmaceuticals discloses new agents for cancer

Soligenix receives grant from NIAID to support development of SGX-943 for melioidosis

Scientists at Sunshine Lake Pharma synthesize novel NS5A inhibitors

Japanese researchers claim new prostanoid EP1 receptor antagonists

FDA issues complete response letters regarding sNDAs for Xarelto

Proximagen designs new PAR-2 antagonists

ViroMed granted FDA orphan drug designation for VM-202-ALS, launches phase I/II trial

New PHD2 inhibitors presented by Taisho Pharmaceutical for anemia

EpiTherapeutics prepares and tests novel KDM5 inhibitors

Novel Ca(v)3.2. blockers disclosed by Kyowa Hakko Kirin

Oxford BioMedica and Sanofi amend terms of agreement for gene-based ocular disease drugs

Cangene shareholders in favor of acquisition

Forest Laboratories to discontinue sale of Namenda tablets

NCI and FDA reach SPA agreement for phase III trial of Syndax's entinostat

Phase III study of mepolizumab in eosinophilic granulomatosis with polyangiitis begins

European COMP recommends orphan drug designation for ISIS-TTRRx

Millennium Pharmaceuticals to conduct PET imaging study of [68Ga]MLN-6907

FDA approves BioMarin's Vimizim for MPS IVA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...